Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Heat Shock who wrote (186)	2/13/2002 6:31:18 PM
From: Heat Shock	Read Replies (1) of 236

To all: conference call notes: - potential partners are especially interested that hspE7 works on refractory warts and that complete responses (clearance of disease) are persistent. - it's conceivable, but unlikely and they are not counting on it, that the RRP orphan drug indication could go to approval after phase II - potential partners are interested in being involved in decisions on PIII and marketing strategy - RRP is likely the "earliest filing" and Stressgen could take that indication to filing alone, without a partner. Pharma partners are required for Genital Warts, and the other indications. - CEO Korpolinsky says they are looking for a "single global partner". He says Stressgen is aiming for an "auction situation" and they have several good possibilities, "all doable deals". He says they are talking to "several large pharmaceutical companies" and partnering is the number one priority. - Stressgen's reagent business has 71% gross margins - Stressgen has several collaborators for Hepatitis B Virus and next in line is Herpes Simplex Virus and then Human Immunodeficiency Virus - heat shock protein fusions induce responses in both the antibody arm and the killer T cell arm of the immune system Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next